Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
GlucoTrack, Inc. (NASDAQ: GCTK) generates news primarily around its progress in implantable continuous blood glucose monitoring technology for people with diabetes and the financing activities that support this development. As a medical device and medical technology company, GlucoTrack regularly issues updates on clinical studies, advisory appointments, scientific presentations, and capital formation transactions.
Visitors to this GCTK news page can review press releases on clinical milestones, including GlucoTrack’s first-in-human study of its long-term implantable Continuous Blood Glucose Monitor (CBGM) and the initiation of a long-term, multicenter feasibility study outside the United States. The company also reports on its plans and interactions related to Investigational Device Exemption (IDE) submissions to the U.S. Food and Drug Administration, as described in its own forward-looking statements.
In addition to clinical updates, GlucoTrack publishes news about its clinical advisory team and patient engagement efforts, such as the appointment of specialists in cardiology, neuromodulation, and pain management, and the formation of a Patient Advisory Board. The company’s participation in diabetes-focused conferences and research initiatives, where it presents data on its blood-based, implantable CBGM system and epidural glucose monitoring work, is another frequent topic.
GlucoTrack’s news flow also covers financing and capital structure developments, including equity purchase agreements, private placements, and warrant repurchases described in its press releases and SEC filings. For investors and observers following GCTK, this page offers a consolidated view of GlucoTrack’s publicly disclosed corporate, clinical, and financial announcements related to its investigational CBGM platform and broader diabetes technology strategy.
Glucotrack Inc. (Nasdaq: GCTK), a medical technology company focused on developing novel technologies for diabetes management, has appointed John Ballantyne, PhD, to its Board of Directors. Ballantyne brings over 20 years of experience from Aldevron, a global biotechnology contract development and manufacturing organization he co-founded. As former Chief Science Officer at Aldevron, Ballantyne has extensive experience in healthcare research, innovation, and strategic growth.
Paul Goode, PhD, President and CEO of Glucotrack, expressed confidence that Ballantyne's expertise will be invaluable as the company expands and moves towards commercializing its novel continuous blood glucose monitoring (CBGM) technology. Ballantyne, who holds a Doctorate in Pharmaceutical Sciences, has developed relationships across various biotechnology sectors through investments and advisory roles.
Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on diabetes management, has announced the appointment of Sandie Martha as Vice President of Clinical Operations. With over 20 years of experience in clinical research, Martha brings expertise in leading global clinical trials for glucose monitoring and cardiology. Her role will be important in executing Glucotrack's Clinical Trial Program for their Continuous Blood Glucose Monitor (CBGM).
Martha's extensive background includes leadership positions at Glysens, Dexcom, and Truvian, where she managed various aspects of clinical trials and regulatory submissions. Her appointment is seen as a strategic move to advance Glucotrack's CBGM technology through clinical trials and ultimately bring it to market for millions of people living with diabetes.
Glucotrack Inc. (Nasdaq: GCTK) presented new findings at the ADCES 2024 Annual Conference, revealing strong interest in their innovative Continuous Blood Glucose Monitor (CBGM) concept. The market research study showed that over 50% of surveyed diabetes patients are open to adopting this new technology.
Key features attracting interest include:
- Long-term sensor life (up to 3 years)
- No wearable component
- Real-time blood glucose readings
The study included 757 respondents with intensive insulin therapy, comprising current CGM users (67%), non-users (25%), and ex-users (8%). Glucotrack's CBGM concept aims to address unmet needs in diabetes management, offering a more convenient and less intrusive monitoring solution. The company has made significant clinical progress, completing successful preclinical studies and planning to initiate human clinical trials later this year.
Glucotrack Inc. (Nasdaq: GCTK) announced a poster presentation at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference in New Orleans, LA, from August 9-12, 2024. The poster, titled 'Evaluating Acceptance of a Continuous Blood Glucose Monitor for Insulin-Requiring People with Diabetes', will showcase market research data on the acceptance of Glucotrack's Continuous Blood Glucose Monitor (CBGM) concept among people with type 1 and type 2 diabetes.
CEO Paul V. Goode emphasized the growing interest in expanding glucose monitoring options. The poster session is scheduled for Saturday, August 10, from 12:15 PM to 1:15 PM Eastern time. Glucotrack will make the poster available on their website following the conference presentation.
Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focusing on diabetes management, has secured $4 million in funding from its leading shareholder, John Ballantyne. This funding will support the upcoming First in Human clinical trial for their innovative Continuous Blood Glucose Monitor (CBGM) technology.
CEO Paul V. Goode, PhD, highlighted the company's significant progress in developing their CBGM technology, describing it as a less burdensome approach to glucose monitoring. Ballantyne expressed confidence in the company's potential to deliver strong clinical value to the diabetes community and meaningful value to shareholders, citing the technology's potential to be disruptive in the large and growing diabetes market.
Glucotrack has appointed Andy Balo to its Board of Directors, effective immediately. Balo, a veteran in the diabetes industry, brings decades of experience in regulatory, clinical, and quality domains. He played a key role in shaping Dexcom over 22 years and has coordinated numerous glucose monitoring regulatory submissions and clinical trials globally. Balo has also held leadership roles at St. Jude Medical, Baxter, Pacesetter, and Endocardial Solutions, and has served on several FDA panels. His expertise will be invaluable as Glucotrack advances its continuous blood glucose monitoring technology through clinical and regulatory milestones.
Glucotrack (Nasdaq: GCTK) has announced the successful completion of a 60-day preclinical study for its innovative epidural continuous glucose monitoring sensor. The sensor, implanted in the epidural space of animals, closely tracked glucose levels comparable to both commercially available blood glucose monitors and subcutaneous CGMs. No abnormal clinical signs or delayed latent effects were observed during the study, supporting the sensor's safety and efficacy. This advancement holds promise for simplifying disease management in patients with painful diabetic neuropathy (PDN), a condition affecting over 7 million Americans. CEO Paul V. Goode expressed confidence in the sensor's performance and its potential benefits for diabetes patients.
Glucotrack (Nasdaq: GCTK), a medical technology company specializing in diabetes management, announced its participation in the Sidoti Small Cap Investor Conference. CEO Paul V. Goode will present on June 12, 2024, at 3:15 PM ET, and will also engage in one-on-one meetings. Interested parties can register for the webcast through a provided link.
Glucotrack announced the successful completion of a 90-day preclinical study for its Continuous Blood Glucose Monitor (CBGM), demonstrating sustained accuracy with a Mean Absolute Relative Difference (MARD) of 4.7%. The study, which involved a larger number of animal subjects than previous studies, showcased the CBGM's ability to offer real-time blood glucose measurement without the lag associated with subcutaneous sensors. The device showed no significant adverse effects and outperformed both a commercial blood glucose monitor and a subcutaneous glucose monitor. Glucotrack plans to initiate human clinical trials later this year.
Glucotrack announced promising results from a 30-day segment of its 60-day long-term preclinical study on an epidural glucose monitoring sensor. The sensor, implanted in the epidural space, successfully tracked blood glucose levels and matched the performance of a commercial subcutaneous CGM. No complications or abnormal clinical signs were observed, showcasing the safety and potential efficacy of the device for managing painful diabetic neuropathy. The ongoing study aims to further validate the sensor's long-term performance and durability, potentially benefiting millions of diabetics if approved.